Evidence map›Paper›PMID 40977229›Full record

ArticleEuropean journal of heart failure2025

Deep phenotyping of heart failure with preserved ejection fraction through multi-omics integration.

Jakob Versnjak, Titus Kuehne, Pauline Fahjen, Nina Jovanovic, Ulrike Löber, Gabriele G Schiattarella, Nicola Wilck, Holger Gerhardt, Dominik N Müller, Frank Edelmann and 6 more

Abstract readMulticenter Study
In one paragraph

Article in European journal of heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Heart Meets Brain: Insights into Neurocardiac Pathophysiology.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jakob VersnjakInstitute of Computer-assisted Cardiovascular Medicine, Deutsches Herzzentrum der Charité, Berlin, Germany.ORCID https://orcid.org/0009-0009-6179-1014
Titus KuehneInstitute of Computer-assisted Cardiovascular Medicine, Deutsches Herzzentrum der Charité, Berlin, Germany.ORCID https://orcid.org/0000-0003-1631-4824
Pauline FahjenProteomics Platform, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.ORCID https://orcid.org/0000-0002-5015-0643
Nina JovanovicCharité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0001-6300-9705
Ulrike LöberCharité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0001-7468-9531
Gabriele G SchiattarellaCharité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0002-7582-7171
Nicola WilckCharité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0003-3189-5364
Holger GerhardtMax Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.ORCID https://orcid.org/0000-0002-3030-0384
Dominik N MüllerCharité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0003-3650-5644
Frank EdelmannCharité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0003-4401-5936
Philipp MertinsCharité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0002-2245-528X
Roland EilsBerlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0002-0034-4036
Michael GotthardtCharité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0003-1788-3172
Sofia K ForslundCharité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0003-4285-6993
Benjamin WildBerlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0002-7492-8448
Marcus KelmInstitute of Computer-assisted Cardiovascular Medicine, Deutsches Herzzentrum der Charité, Berlin, Germany.ORCID https://orcid.org/0000-0003-4971-0452

Funding

Bundesministerium für Bildung und Forschung 01EJ2406ADeutsche Forschungsgemeinschaft: SFB-1470- A02,A03,A05,A06,A10,B04,B05,Z02,Z03Deutsches Zentrum für Herz-Kreislaufforschung 81X3100210,81X2100282,81Z0100106Foundation Leducq 21CVD02H2020 European Research Council 101078307
6 · The paper itself

Abstract

aimsHeart failure with preserved ejection fraction (HFpEF) has become the predominant form of heart failure and a leading cause of global cardiovascular morbidity and mortality. Due to its heterogeneous nature, HFpEF presents substantial challenges in diagnosis and management. Given the limited treatment options and lifestyle-associated comorbidities, early identification is crucial for establishing effective preventive strategies. Here, we introduce and validate a machine learning-based multi-omics approach that integrates clinical and molecular data to detect and characterize HFpEF. METHODS AND

resultsA supervised classifier was trained on a stratified subset of UK Biobank participants (n = 401 917) to identify phenotypic profiles associated with subsequent symptom-defined HFpEF during longitudinal follow-up. Model performance was validated in a non-overlapping hold-out subset from all 22 UK Biobank assessment centres (n = 100 446; 6726 HFpEF cases; 7394 with multi-omics data). The classifier demonstrated robust discriminatory performance, with a receiver operating characteristic area under the curve (ROC AUC) of 0.931 (95% confidence interval [CI] 0.930-0.931), a sensitivity of 0.857 (95% CI 0.855-0.860) and a specificity of 0.847 (95% CI 0.846-0.847). It identified individuals who subsequently developed HFpEF an average of 6.3 ± 3.9 years before symptom onset in asymptomatic individuals. Similarity network fusion (SNF) identified distinct subgroups, including a high-risk cluster characterized by elevated mortality and dysregulated inflammatory pathways, which was distinguishable with high accuracy (ROC AUC 0.988; 95% CI 0.985-0.990).

conclusionsWe identified HFpEF phenotypes at an early stage, often several years before the onset of clinical symptoms, when the disease trajectory may still be amenable to modification. The molecular characterization provides novel insights into the underlying disease complexity and enables more refined risk stratification.

Indexed as

Heart FailureMachine LearningStroke VolumeAgedFemaleHumansMaleMiddle AgedMultiomicsPhenotypeROC CurveUnited KingdomAI, artificial intelligenceExplainable artificial intelligenceHeart Failure Stage A: At Risk for Heart FailureHeart Failure Stage B: Pre‐Heart FailureHeart failure with preserved ejection fractionMachine learningMulti‐omicsPre‐symptomatic heart failure

Identifiers

PMID40977229
PMCPMC12803610

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.